Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBYOT.L Share News (BYOT)

  • There is currently no data for BYOT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Jorge Cosmen raises National Express stake

Fri, 20th Nov 2009 17:28

Shares in National Express raced ahead after deputy chairman Jorge Cosmen increased his family's influence over the company, spending more than £1.7m on shares in the train and bus operator.He bought just over 500,000 shares at 341p a time and now has about 29m, which is just shy of 20% of the company.The Cosmen family, a Spanish dynasty specialising in transport, recently teamed up with private equity group CVC to launch a bid for National Express but then withdrew their interest after negotiations.National Express later rejected a merger offer from its rival Stagecoach, instead opting to raise funds from shareholders through a rights issue.The rejection of the Stagecoach offer prompted criticism from the Cosmen family, which said it was 'concerned that there has not been a sufficiently full and thorough assessment of all the available options to address the company's short and longer-term challenges.'Among the challenges National Express has faced are the loss of the East Coast rail franchise, which it walked away from after seeing revenues fall. The firm now has just two rail franchises, the c2c service between London and south Essex and the East Anglia line that runs between London and Norwich. Top Director BuysNational Express Group (NEX) Director name: Mr Jorge CosmenAmount purchased: 501,823 @ 341.00p Value: £1,711,216Cable & Wireless (CW.) Director name: Mr Timothy PenningtonAmount purchased: 336,986 @ 139.46p Value: £469,961Cable & Wireless (CW.) Director name: Mr John PlutheroAmount purchased: 150,000 @ 138.91p Value: £208,365Healthcare Locums (HLO) Director name: Ms Kate BleasdaleAmount purchased: 50,000 @ 252.00p Value: £126,000Mecom Group (MEC) Director name: Mr David MontgomeryAmount purchased: 20,000 @ 145.00p Value: £29,000Byotrol (BYOT) Director name: Mr Iain Duncan SmithAmount purchased: 65,000 @ 31.00p Value: £20,150Byotrol (BYOT) Director name: Dr. Till MedingerAmount purchased: 65,000 @ 31.00p Value: £20,150Top Director SellsBankers Petroleum Ltd (BNK) Director name: Mr Robert M D CrossAmount sold: 1,000,000 @ 284.62p Value: £2,846,200Unite Group (UTG) Director name: Mr Mark AllenAmount sold: 54,733 @ 280.30p Value: £153,417
More News
21 Dec 2009 12:00

London midday: Oil fired Footsie

Oil is fuelling the Footsie's rise today, with support from back-in-favour banks. Cairn Energy has secured a drill ship to get an early start on its exploration activities in Greenland. The oil company said drilling in Greenland will start a year ahead of schedule after it came to a deal with Hess

Read more
21 Dec 2009 08:59

US patent boosts Byotrol

Germ killing technology company Byotrol's share price received a boost after it said that it had its US patent application accepted. Byotrol, which applied for the patent in 2002, said the patent runs until 2022. Meanwhile, a Fortune 150 multinational company has paid Byotrol and its joint ventur

Read more
17 Nov 2009 14:37

Byotrol's bumper interim revenues

Anti-microbial technology developer Byotrol reported strong revenue growth in the six months to September 2009 but this rate of growth will be difficult to maintain. Revenues jumped from £388,000 to £2m - more than double the level for the previous 12 months. Publicity about swine flu and other in

Read more
17 Sep 2009 08:39

Small caps round-up: Byotrol, ReNeuron, Accuma...

Germ-killing product supplier Byotrol said it has seen a significant increase in orders and now expects results for the financial year to September 30 to be ahead of expectations. Shares in Meridian Petroleum gushed higher after the oil and gas firm announced an increase in prospective resources in

Read more
16 Jun 2009 14:18

Kugler appointed chairman at Byotrol

Germ killing product developer Byotrol saw losses widen and sales slide slightly last year but said the current outlook is promising, as test results demonstrate the effectiveness of its hygiene technology. Revenue in the year to 31 March 2009 eased to £0.93m from £0.95m the year before, while loss

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.